Molecular mechanisms of sulfasalazine‐induced T‐cell apoptosis

[1]  R. Schmid,et al.  Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β , 2000 .

[2]  G. Kroemer,et al.  Apoptosis Control in Syncytia Induced by the HIV Type 1–Envelope Glycoprotein Complex , 2000, The Journal of experimental medicine.

[3]  Tak W. Mak,et al.  Two Distinct Pathways Leading to Nuclear Apoptosis , 2000, The Journal of experimental medicine.

[4]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[5]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[6]  Guido Kroemer,et al.  Apoptosis‐inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis , 2000, FEBS letters.

[7]  R. Schmid,et al.  NF-κB/Rel/IκB: Implications in gastrointestinal diseases , 2000 .

[8]  Y Li,et al.  [Mitochondria and apoptosis]. , 2000, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine].

[9]  P. Krammer,et al.  The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. , 2000, Experimental cell research.

[10]  A. Strasser,et al.  Ionizing Radiation and Chemotherapeutic Drugs Induce Apoptosis in Lymphocytes in the Absence of FAS or Fadd/Mort1 Signaling Implications for Cancer Therapy , 2000 .

[11]  R. Schmid,et al.  Inhibition of nuclear factor kappa B and induction of apoptosis in T‐lymphocytes by sulfasalazine , 1999, British journal of pharmacology.

[12]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[13]  Masashi Narita,et al.  Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC , 1999, Nature.

[14]  M. Peter,et al.  Apoptosis signaling in lymphocytes. , 1999, Current opinion in immunology.

[15]  Y. Tao,et al.  NF-κB functions as both a proapoptotic and antiapoptotic regulatory factor within a single cell type , 1999, Cell Death and Differentiation.

[16]  R. Tersigni,et al.  Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. , 1999, Gastroenterology.

[17]  M. Schwab,et al.  MycN sensitizes neuroblastoma cells for drug-induced apoptosis , 1999, Oncogene.

[18]  Ruedi Aebersold,et al.  Molecular characterization of mitochondrial apoptosis-inducing factor , 1999, Nature.

[19]  I. Herr,et al.  JNK/SAPK activity is not sufficient for anticancer therapy‐induced apoptosis involving CD95‐L, TRAIL and TNF‐α , 1999, International journal of cancer.

[20]  S. Korsmeyer,et al.  Regulated Targeting of BAX to Mitochondria , 1998, The Journal of cell biology.

[21]  T. Griffith,et al.  TRAIL: a molecule with multiple receptors and control mechanisms. , 1998, Current opinion in immunology.

[22]  J C Reed,et al.  Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. , 1998, Science.

[23]  S. Korsmeyer,et al.  Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis , 1998, The EMBO journal.

[24]  John Calvin Reed,et al.  Bcl-2 family proteins as ion-channels , 1998, Cell Death and Differentiation.

[25]  J C Reed,et al.  Bax directly induces release of cytochrome c from isolated mitochondria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Kroemer,et al.  Disruption of the outer mitochondrial membrane as a result of large amplitude swelling: the impact of irreversible permeability transition , 1998, FEBS letters.

[27]  R. Schmid,et al.  Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. , 1998, The Journal of clinical investigation.

[28]  S. Nagata,et al.  A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.

[29]  Yi-Te Hsu,et al.  Movement of Bax from the Cytosol to Mitochondria during Apoptosis , 1997, The Journal of cell biology.

[30]  M. V. Heiden,et al.  Bcl-xL Regulates the Membrane Potential and Volume Homeostasis of Mitochondria , 1997, Cell.

[31]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[32]  I. Herr,et al.  The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. , 1997, Cancer research.

[33]  W. Earnshaw,et al.  Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. , 1997, Blood.

[34]  G. Kroemer.  The proto-oncogene Bcl-2 and its role in regulating apoptosis , 1997, Nature Medicine.

[35]  G. Kroemer,et al.  The Central Executioner of Apoptosis: Multiple Connections between Protease Activation and Mitochondria in Fas/APO-1/CD95- and Ceramide-induced Apoptosis , 1997, The Journal of experimental medicine.

[36]  Xiaodong Wang,et al.  DFF, a Heterodimeric Protein That Functions Downstream of Caspase-3 to Trigger DNA Fragmentation during Apoptosis , 1997, Cell.

[37]  Y. Hsu,et al.  Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[39]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[40]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[41]  P. Emery,et al.  Inhibition of T cell apoptosis in the rheumatoid synovium. , 1997, The Journal of clinical investigation.

[42]  G. Anderson.  Resolution of chronic inflammation by therapeutic induction of apoptosis. , 1996, Trends in pharmacological sciences.

[43]  G. Kroemer,et al.  Bcl-2 inhibits the mitochondrial release of an apoptogenic protease , 1996, The Journal of experimental medicine.

[44]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[45]  A. Strasser,et al.  Bcl‐2 and Fas/APO‐1 regulate distinct pathways to lymphocyte apoptosis. , 1995, The EMBO journal.

[46]  Patrick R. Griffin,et al.  Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis , 1995, Nature.

[47]  Muneesh Tewari,et al.  Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase , 1995, Cell.

[48]  H. Ishii,et al.  Restricted usage of immunoglobulin heavy chain variable region (VH3) in B cell clones producing anti-colon antibodies in ulcerative colitis , 1995 .

[49]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[50]  D. Munn,et al.  Activation-induced apoptosis in human macrophages: developmental regulation of a novel cell death pathway by macrophage colony- stimulating factor and interferon gamma , 1995, The Journal of experimental medicine.

[51]  J. Mountz,et al.  Autoimmune disease. A problem of defective apoptosis. , 1994, Arthritis and rheumatism.

[52]  C. Bloch,et al.  Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. , 1994, Cancer research.

[53]  A. Modica,et al.  Detection and characterization of apoptotic peripheral blood lymphocytes in human immunodeficiency virus infection and cancer chemotherapy by a novel flow immunocytometric method. , 1994, Blood.

[54]  T. Honjo,et al.  The bcl-2 gene product inhibits clonal deletion of self-reactive B lymphocytes in the periphery but not in the bone marrow , 1993, The Journal of experimental medicine.

[55]  P. Krammer,et al.  Activation interferes with the APO-1 pathway in mature human T cells. , 1993, International immunology.

[56]  O. Janssen,et al.  Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. , 1993, Journal of immunology.

[57]  C. Haslett.  Resolution of acute inflammation and the role of apoptosis in the tissue fate of granulocytes. , 1992, Clinical science.

[58]  Gary J. Nabel,et al.  Cloning of an NF-κB subunit which stimulates HIV transcription in synergy with p65 , 1991, Nature.

[59]  H. Macdonald,et al.  Programmed death of autoreactive thymocytes , 1990, Nature.

[60]  D. Heijde,et al.  EFFECTS OF HYDROXYCHLOROQUINE AND SULPHASALAZINE ON PROGRESSION OF JOINT DAMAGE IN RHEUMATOID ARTHRITIS , 1989, The Lancet.

[61]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[62]  B. McConkey,et al.  Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. , 1983, British medical journal.

[63]  J. McManus,et al.  The metabolism of salicylazosulphapyridine in ulcerative colitis , 1973, Gut.

[64]  M. Peppercorn,et al.  Distribution studies of salicylazosulfapyridine and its metabolites. , 1973, Gastroenterology.

[65]  D. Isenberg,et al.  Apoptosis in human autoimmune diseases. , 1999, International reviews of immunology.

[66]  K O'Rourke,et al.  Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. , 1995, Cell.

[67]  P. Andrews,et al.  Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65. , 1991, Nature.

[68]  H. Cox,et al.  Letter: Moorgate tube disaster: disputed alcohol findings. , 1975, Lancet.

[69]  O. Bonnevie,et al.  The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A double-blind trial on patients asymptomatic for one year. , 1973, Scandinavian journal of gastroenterology.